Arş. Gör. ÖZLEN BEKTAŞ

1. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems

BEKTAŞ Ö., ÜNER A., ELİAÇIK E., Uz B., Isik A., ETGÜL S., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.2, ss.119-126, 2016 (SCI-Expanded, Scopus, TRDizin)

2. High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology

BEKTAŞ Ö., ÜNER A., Aydin S. M., ELİAÇIK E., Uz B., Isik A., et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY , cilt.102, sa.2, ss.211-217, 2015 (SCI-Expanded, Scopus)

3. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML

Malkan U. Y., AKSU S., Aktimur S. H., Atay H., Bektas O., BÜYÜKAŞIK Y., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.25, sa.4, ss.215-221, 2015 (SCI-Expanded, Scopus, TRDizin)

4. Vitamin B-12 Deficiency with the Absence of Anemia in Young and Middle-Aged Population

Kara A., Eliacik E., BÜYÜKAŞIK Y., ÖZCEBE O. İ., Haznedaroglu I., AKSU S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.3, ss.190-194, 2014 (SCI-Expanded, Scopus, TRDizin)

5. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate

Uz B., BÜYÜKAŞIK Y., Atay H., KELKİTLİ E., Turgut M., BEKTAŞ Ö., et al.

HEMATOLOGY , cilt.18, sa.5, ss.247-252, 2013 (SCI-Expanded, Scopus)

6. Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis

Uz B., SAİN GÜVEN G., Isik A., KUYUMCU M. E., BEKTAŞ Ö., ELİAÇIK E., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.19, sa.3, ss.338-340, 2013 (SCI-Expanded, Scopus)

7. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia

BOZKURT S., Uz B., BÜYÜKAŞIK Y., BEKTAŞ Ö., Inanc A., GÖKER H., et al.

MEDICAL ONCOLOGY , cilt.30, sa.1, 2013 (SCI-Expanded, Scopus)

8. Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study

BÜYÜKAŞIK Y., Acar K., Kelkitli E., UZ B., SEREFHANOGLU S., Ozdemir E., et al.

ACTA HAEMATOLOGICA , cilt.130, sa.3, ss.199-205, 2013 (SCI-Expanded, Scopus)

9. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Hypertensive Patients and a Comparison of the Effects of Amlodipine and Ramipril on TAFI Levels

Ozkan G., ULUSOY Ş., SÖNMEZ M., KARAHAN S. C., MENTEŞE A., Kaynar K., et al.

CLINICAL AND EXPERIMENTAL HYPERTENSION , cilt.35, sa.2, ss.134-140, 2013 (SCI-Expanded, Scopus)

10. Nasal Natural Killer/T-cell Lymphoma with Skin, Eye, and Peroneal Nerve Involvement

Turker B., Uz B., Isik M., BEKTAŞ Ö., DEMİROĞLU H., SAYINALP N., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.29, sa.4, ss.413-419, 2012 (SCI-Expanded, Scopus, TRDizin)

11. Giant Abdominopelvic Haematoma Arising from Ovulation in a Glanzmann's Thrombasthenia Patient with Platelet Refractoriness: Treatment with Surgery and Intra-Abdominal Tranexamic Acid

BÜYÜKAŞIK Y., BOYRAZ G., Selcuk I., BEKTAŞ Ö., TUNCER Z. S.

ACTA HAEMATOLOGICA , cilt.128, sa.3, ss.154-157, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML

AKSU S., BEKTAŞ Ö., Uz B., BÜYÜKAŞIK Y., SAYINALP N., Ozcebe O., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.1-7, 2012 (SCI-Expanded, Scopus, TRDizin)

13. Dasatinib-Induced Tumor Lysis Syndrome and Following Hematologic Remission in Fibrotic Blastic Crisis of CML

BEKTAŞ Ö., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., GÖKER H., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.2, ss.13-16, 2010 (SCI-Expanded, Scopus, TRDizin)

Arş. Gör. ÖZLEN BEKTAŞ

Yayınlar & Eserler

1. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems

2. High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology

3. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML

4. Vitamin B-12 Deficiency with the Absence of Anemia in Young and Middle-Aged Population

5. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate

6. Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis

7. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia

8. Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study

9. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Hypertensive Patients and a Comparison of the Effects of Amlodipine and Ramipril on TAFI Levels

10. Nasal Natural Killer/T-cell Lymphoma with Skin, Eye, and Peroneal Nerve Involvement

11. Giant Abdominopelvic Haematoma Arising from Ovulation in a Glanzmann's Thrombasthenia Patient with Platelet Refractoriness: Treatment with Surgery and Intra-Abdominal Tranexamic Acid

12. Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML

13. Dasatinib-Induced Tumor Lysis Syndrome and Following Hematologic Remission in Fibrotic Blastic Crisis of CML

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim